Founded in Quebec City in 2015, diaMentis develops a technology resulting from the research work of Laval University to develop a tool for diagnostic support in mental health.

Financial contributions have been granted to Laval University by the Consortium québécois sur la découverte du médicament (CQDM) and by the Canadian Institutes for Health Research (CIHR). Support from many important partners, such as the team from the Société de valorisation SOVAR, and many strategic investors, have also enabled this high-tech project to take shape.

diaMentis uses a non-invasive test based on reliable analysis of information from ERG assessment (biosignatures).

diaMentis wants to improve patient care by providing clinicians with a tool for objective and quantitative diagnosis that should be included in the medical treatment guidelines.

diaMentis is the first company to develop a software as medical device (SaMD) that analyses information from a simple examination of the eye (electroretinography).

diaMentis is a spin-off from Laval University.  Its team includes experienced life science entrepreneurs who have contributed to the development of many world-renowned companies.

The team

Normand Tremblay

C.Dir., M.Sc., C.Adm., C.M.C.

President, Chief Executive Officer (CEO)

Bernard Guimont

B.A., C.Adm.

Vice President, Chief Financial and Operating Officer (CFOO)

Claude Hariton

Ph.D., D.Sc.

Vice President, Chief Scientific Officer (CSO)

Yves Lachance

Ph.D., C.Adm.

Vice President, Regulatory Affairs and Compliance

Claudia Émond


Manager, Biostatistics and Data Management

Alexandre Sasseville


ERG Manager

Frédéric Thibault

B.A., D.E.S.S.

Project Manager


Develop, valorise, patent and market (directly or indirectly) a diagnostic tool for better management of patients with mental disorders in a personalised healthcare environment.


To become a global reference in mental health with a personalised medicine approach for better efficiency of available resources for all stakeholders involved in mental healthcare mainly throughout Canada, the United States and Europe.

Value Proposition

Improve patient healthcare by integrating a new approach that allows healthcare professionals using a non-invasive diagnostic tool with sufficient performance in terms of predictive value, ease of use and accessibility.